Daiichi Sankyo and Sarah Cannon Research Institute closed a strategic oncology development collaboration under which the CRO will provide comprehensive clinical development services and operational delivery to several of Daiichi Sankyos translational development programs. The collaboration will enable rapid patient enrollment to clinical trials through Sarah Cannons extensive research network across the U.S. and UK, which serves thousands of patients annually in clinical trials, as well as through Daiichi Sankyos clinical network in Japan.